Related Experiment Video
Updated: May 10, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
[Future drug targets for Parkinson's disease]
1INSERM UMR 975, CNRS UMR 7225, Université Pierre et Marie Curie Paris 06, Institut du cerveau et de la moelle épinière, Hôpital de la Salpêtrière, Paris. etienne.hirsch@upmc.fr
Bulletin De L'Academie Nationale De Medecine
|July 3, 2013
Summary
Parkinson's disease involves motor symptoms from neuron loss. This review explores neuroprotection targets and treatments for non-dopaminergic symptoms, aiming to halt degeneration.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Context:
- Parkinson's disease (PD) is a neurodegenerative disorder defined by motor symptoms like bradykinesia, rigidity, and tremor.
- These symptoms arise from the progressive loss of dopaminergic neurons in the substantia nigra, a hallmark of this synucleinopathy.
- Current treatments, including dopaminergic drugs and deep brain stimulation, manage symptoms but do not halt disease progression.
Purpose:
- To review the underlying mechanisms of neuronal degeneration in Parkinson's disease.
- To identify and discuss novel therapeutic targets for neuroprotection.
- To examine the causes of treatment-resistant symptoms linked to non-dopaminergic pathways.
Summary:
- Examines the complex mechanisms driving neuronal loss in Parkinson's disease.
- Highlights emerging strategies and targets for neuroprotective interventions.
- Investigates the pathophysiology of symptoms unresponsive to current dopaminergic therapies.
Impact:
- Provides insights into potential disease-modifying therapies for Parkinson's disease.
- Offers a foundation for developing treatments that address the full spectrum of PD symptoms.
- Advances understanding of neurodegeneration in synucleinopathies and Lewy body disorders.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...